Proliferation and metastatic potential of endometrial cancer cells in response to metformin treatment in a high versus normal glucose environment

Oncology Letters

Volumn 12, Issue 5, 2016, Pages 3626-3632

  Machado, Amanda De Barros ^a,b,c   Dos Reis, Vania ^a,b   Weber, Sebastian ^c   Jauckus, Julia ^c   Brum, Ilma Simoni ^a,b   Von Eye Corleta, Helena ^a,b   Strowitzki, Thomas ^c   Capp, Edison ^a,b,c   Germeyer, Ariane ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Cancer development; Endometrial cancer; Glucose; Hyperinsulinemia; Metastasis; Metformin

Indexed keywords

GLUCOSE; INSULIN; METFORMIN;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; HUMAN; HUMAN CELL; METASTASIS;

EID: 84990065842     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5041     Document Type: Article

References (33)

1. No authors listed: Cancer statistics. JAMA 310: 982, 2013.
2. Garg K and Soslow RA: Endometrial carcinoma in women aged 40 years and younger. Arch Pathol Lab Med 138: 335-342, 2014.
3. Clarke CL and Sutherland RL: Progestin regulation of cellular proliferation. Endocr Rev 11: 266-301, 1990.
4. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A; Australian National Endometrial Cancer Study Group (ANECS), Perry JR, Attia J, et al: Evidence of a causal association between insulinemia and endometrial cancer: A mendelian randomization analysis. J Natl Cancer Inst 107: pii: djv178, 2015.
5. Szablewski L: Diabetes mellitus: Influences on cancer risk. Diabetes Metab Res Rev 30: 543-553, 2014.
6. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, et al: Endometrial cancer: A review and current management strategies: Part I. Gynecol Oncol 134: 385-392, 2014.
7. Mu N, Zhu Y, Wang Y, Zhang H and Xue F: Insulin resistance: A significant risk factor of endometrial cancer. Gynecol Oncol 125: 751-757, 2012.
8. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC and Brancati FL: Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 300: 2754-2764, 2008.
9. Friberg E, Orsini N, Mantzoros CS and Wolk A: Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia 50: 1365-1374, 2007.
10. Bowers LW, Rossi EL, O’Flanagan CH, deGraffenried LA and Hursting SD: The role of the insulin/IGF system in cancer: Lessons learned from clinical trials and the energy balance-cancer link. Front Endocrinol (Lausanne) 6: 77, 2015.
11. Gallagher EJ and LeRoith D: Obesity and diabetes: The increased risk of cancer and cancer-related mortality. Physiol Rev 95: 727-748, 2015.
12. Shao R, Li X, Feng Y, Lin JF and Billig H: Direct effects of metformin in the endometrium: A hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. J Exp Clin Cancer Res 33: 41, 2014.
13. Umene K, Banno K, Kisu I, Yanokura M, Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, et al: New candidate therapeutic agents for endometrial cancer: Potential for clinical practice (review). Oncol Rep 29: 855-860, 2013.
14. Febbraro T, Lengyel E and Romero IL: Old drug, new trick: Repurposing metformin for gynecologic cancers? Gynecol Oncol 135: 614-621, 2014.
15. He H, Ke R, Lin H, Ying Y, Liu D and Luo Z: Metformin, an old drug, brings a new era to cancer therapy. Cancer J 21: 70-74, 2015.
16. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M and Andreelli F: Cellular and molecular mechanisms of metformin: An overview. Clin Sci (Lond) 122: 253-270, 2012.
17. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 116: 92-98, 2010.
18. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One 8: e71583, 2013.
19. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA and Bae-Jump V: Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 132: 438-442, 2014.
20. Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M and Bidadi S: Antiproliferative effect of metformin on the endometrium-a clinical trial. Asian Pac J Cancer Prev 15: 10067-10070, 2014.
21. Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int 14: 53, 2014.
22. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I and Werner H: Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One 8: e61537, 2013.
23. Wu B, Li S, Sheng L, Zhu J, Gu L, Shen H, La D, Hambly BD, Bao S and Di W: Metformin inhibits the development and metastasis of ovarian cancer. Oncol Rep 28: 903-908, 2012.
24. Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Res 74: 4783-4795, 2014.
25. Bao B, Azmi AS, Ali S, Zaiem F and Sarkar FH: Metformin may function as anti-cancer agent via targeting cancer stem cells: The potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med 2: 59, 2014.
26. Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I and Hammar N: Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. Cancer Causes Control 22: 1163-1171, 2011.
27. Moran LJ, Hutchison SK, Norman RJ and Teede HJ: Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev: CD007506, 2011.
28. Sinnett-Smith J, Kisfalvi K, Kui R and Rozengurt E: Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 430: 352-357, 2013.
29. Menendez JA, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, Joven J, Martin-Castillo B and Vazquez-Martin A: Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 11: 2782-2792, 2012.
30. Zhuang Y, Chan DK, Haugrud AB and Miskimins WK: Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS One 9: e108444, 2014.
31. Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H and Suzuki K: Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 461: 115-121, 2015.
32. Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu F and Yu P: Metformin inhibits the proliferation, metastasis, and cancer stem-like sphere formation in osteosarcoma MG63 cells in vitro. Tumour Biol 36: 9873-9883, 2015.
33. Han J, Zhang L, Guo H, Wysham WZ, Roque DR, Willson AK, Sheng X, Zhou C and Bae-Jump VL: Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling. Gynecol Oncol 138: 668-675, 2015.